Details of the Drug Combination

General Information of Drug Combination (ID: DCNGR58)

• Drug Combination Name: Terameprocol + Plicamycin
• Indication: Renal cell carcinoma; Status: Investigative [1]
• Component Drugs:
  Terameprocol (DMC3P45): Small molecular drug
  Plicamycin (DM7C8YV): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: SN12C
  Zero Interaction Potency (ZIP) Score: 2.12
  Bliss Independence Score: 7.52
  Loewe Additivity Score: 2.69
  LHighest Single Agent (HSA) Score: 2.69

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[2]

Indication(s) of Plicamycin

Disease Entry	ICD 11	Status	REF
Hypercalcaemia	5B91.0	Approved	[3]
Testicular cancer	2C80	Approved	[3]
Solid tumour/cancer	2A00-2F9Z	Withdrawn from market	[4]
Lung cancer	2C25.0	Investigative	[5]
Ovarian cancer	2C73	Investigative	[5]

Plicamycin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
RNA synthesis (hRNA synth)	TTX2AYW	NOUNIPROTAC	Modulator	[7]

Plicamycin Interacts with 8 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)	OT3K7HY5	DHB2_HUMAN	Decreases Expression	[8]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[9]
Proto-oncogene tyrosine-protein kinase Src (SRC)	OTETYX40	SRC_HUMAN	Decreases Expression	[10]
Tyrosine-protein kinase receptor UFO (AXL)	OTKA2SUX	UFO_HUMAN	Decreases Expression	[11]
Transcription factor Sp3 (SP3)	OTYDQZ1T	SP3_HUMAN	Decreases Expression	[6]
Epidermal growth factor receptor kinase substrate 8 (EPS8)	OTZ6ES6V	EPS8_HUMAN	Decreases Expression	[10]
TNFAIP3-interacting protein 1 (TNIP1)	OTRAOTEW	TNIP1_HUMAN	Decreases Expression	[12]
Sphingomyelin phosphodiesterase 3 (SMPD3)	OTHQBETH	NSMA2_HUMAN	Decreases Expression	[13]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DCFMKQ0	HL-60(TB)	Investigative	[1]
Clear cell renal cell carcinoma	DCGMU0I	CAKI-1	Investigative	[1]
Carcinoma	DCFG3ZG	RXF 393	Investigative	[14]
Colon carcinoma	DC6SICZ	KM12	Investigative	[14]
Invasive ductal carcinoma	DC5TS2A	BT-549	Investigative	[14]
Adenocarcinoma	DC8N6HM	OVCAR3	Investigative	[15]
Adenocarcinoma	DCNO67S	A549	Investigative	[15]
Adenocarcinoma	DCA1X0C	HCT116	Investigative	[15]
Adenocarcinoma	DCHQQ2D	SW-620	Investigative	[15]
Adenocarcinoma	DCIOUEH	HT29	Investigative	[15]
Amelanotic melanoma	DCRB2WP	M14	Investigative	[15]
Cutaneous melanoma	DCV1IUB	SK-MEL-5	Investigative	[15]
Cutaneous melanoma	DCC4DMF	SK-MEL-28	Investigative	[15]
High grade ovarian serous adenocarcinoma	DCQLD62	OVCAR-5	Investigative	[15]
High grade ovarian serous adenocarcinoma	DC1A1MT	NCI\\/ADR-RES	Investigative	[15]
Large cell lung carcinoma	DCYV82U	NCI-H460	Investigative	[15]
Lung adenocarcinoma	DCE0FSS	HOP-62	Investigative	[15]
Malignant melanoma	DCB2T51	UACC62	Investigative	[15]
Minimally invasive lung adenocarcinoma	DCCLIO4	NCI-H322M	Investigative	[15]
Mixed endometrioid and clear cell carcinoma	DCRYMVF	IGROV1	Investigative	[15]
Pleural epithelioid mesothelioma	DCRH23D	NCI-H226	Investigative	[15]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
• [2] Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8394).
• [5] The Pluripotency Factor Musashi-2 Is a Novel Target for Lung Cancer Therapy.Ann Am Thorac Soc. 2018 Apr;15(Supplement_2):S124.
• [6] The activity of a novel mithramycin analog is related to its binding to DNA, cellular accumulation, and inhibition of Sp1-driven gene transcription. Chem Biol Interact. 2014 Aug 5;219:123-32. doi: 10.1016/j.cbi.2014.05.019. Epub 2014 Jun 4.
• [7] Role of magnesium ion in mithramycin-DNA interaction: binding of mithramycin-Mg2+ complexes with DNA. Biochemistry. 1995 Jan 31;34(4):1376-85.
• [8] SP1 and SP3 mediate progesterone-dependent induction of the 17beta hydroxysteroid dehydrogenase type 2 gene in human endometrium. Biol Reprod. 2006 Oct;75(4):605-14.
• [9] Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem. 2007 Jan 26;282(4):2615-25. doi: 10.1074/jbc.M606203200. Epub 2006 Nov 22.
• [10] Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. Chem Biol Interact. 2010 Jan 5;183(1):181-6. doi: 10.1016/j.cbi.2009.09.018.
• [11] The human receptor tyrosine kinase Axl gene--promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep. 2008 Jun;28(3):161-76. doi: 10.1042/BSR20080046.
• [12] Sp sites contribute to basal and inducible expression of the human TNIP1 (TNF-inducible protein 3-interacting protein 1) promoter. Biochem J. 2013 Jun 15;452(3):519-29. doi: 10.1042/BJ20121666.
• [13] Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta. 2009 Nov-Dec;1789(11-12):681-90. doi: 10.1016/j.bbagrm.2009.08.006. Epub 2009 Aug 19.
• [14] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
• [15] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976